In vivo, 2′,4′-DHC suppressed tumor growth and enhanced oxaliplatin efficacy without systemic toxicity, highlighting the translational promise of combining ERO1α inhibition with ferroptosis inducers and chemotherapy [57]. Here, ERO1A is linked to neoplasm.